{"id":"https://openalex.org/W2018774200","doi":"https://doi.org/10.1007/s11523-011-0172-y","title":"Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma","display_name":"Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma","publication_year":2011,"publication_date":"2011-03-01","ids":{"openalex":"https://openalex.org/W2018774200","doi":"https://doi.org/10.1007/s11523-011-0172-y","mag":"2018774200","pmid":"https://pubmed.ncbi.nlm.nih.gov/21484496","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3253822"},"language":"en","primary_location":{"id":"doi:10.1007/s11523-011-0172-y","doi":"https://doi.org/10.1007/s11523-011-0172-y","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11523-011-0172-y","pdf_url":null,"source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3253822","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041033274","display_name":"Sumanta Kumar Pal","orcid":"https://orcid.org/0000-0002-1712-0848","observed_orcids":["https://orcid.org/0000-0002-1712-0848"]},"institutions":[{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sumanta Kumar Pal","raw_affiliation_strings":["Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA. spal@coh.org","Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA. spal@coh.org","institution_ids":["https://openalex.org/I4210110459"]},{"raw_affiliation_string":"Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I4210110459"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050649350","display_name":"Robert A. Figlin","orcid":"https://orcid.org/0000-0002-6323-6075","observed_orcids":["https://orcid.org/0000-0002-6323-6075"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Figlin","raw_affiliation_strings":["Academic Program Development, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA","David Geffen School of Medicine at UCLA, 8700 Beverly Blvd., AC 1042-B, North Tower, Los Angeles, CA, 90048, USA","Division of Hematology Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Academic Program Development, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA","institution_ids":[]},{"raw_affiliation_string":"David Geffen School of Medicine at UCLA, 8700 Beverly Blvd., AC 1042-B, North Tower, Los Angeles, CA, 90048, USA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Division of Hematology Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5041033274"],"corresponding_institution_ids":["https://openalex.org/I4210110459"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":null,"fwci":0.7297,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.57259802,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"6","issue":"1","first_page":"5","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9419999718666077},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9599999785423279},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.878000020980835},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8999999761581421},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8240000009536743},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.8600000143051147},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.7789999842643738},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8370000123977661},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.5389999747276306},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.6669999957084656},{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":0.9900000095367432},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0}],"concepts":[{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.9888204336166382},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.9191998243331909},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.910216212272644},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.871537983417511},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8535166382789612},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8431941270828247},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6805803775787354},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.6467350125312805},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.6267573237419128},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5805037021636963},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.5763049125671387},{"id":"https://openalex.org/C2777921159","wikidata":"https://www.wikidata.org/wiki/Q32089","display_name":"Sirolimus","level":2,"score":0.5667689442634583},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5077934861183167},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4797702729701996},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4548006057739258},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3906458616256714},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3636552691459656},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3608652949333191},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2409653663635254},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.21973246335983276},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1458004117012024},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.10937643051147461},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07083284854888916},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068338","descriptor_name":"Everolimus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000903","descriptor_name":"Antibiotics, Antineoplastic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000903","descriptor_name":"Antibiotics, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s11523-011-0172-y","doi":"https://doi.org/10.1007/s11523-011-0172-y","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11523-011-0172-y","pdf_url":null,"source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},{"id":"pmid:21484496","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21484496","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3253822","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3253822","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Target Oncol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:3253822","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3253822","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Target Oncol","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/1","display_name":"No poverty","score":0.46000000834465027}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6104376904","display_name":"City of Hope Clinical Oncology Career Research Development Program","funder_award_id":"K12CA001727","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":54,"referenced_works":["https://openalex.org/W591006708","https://openalex.org/W1899213880","https://openalex.org/W1966267239","https://openalex.org/W1971936145","https://openalex.org/W1986972767","https://openalex.org/W1997050190","https://openalex.org/W1999966467","https://openalex.org/W2008520239","https://openalex.org/W2055534473","https://openalex.org/W2058741232","https://openalex.org/W2081121624","https://openalex.org/W2082248956","https://openalex.org/W2085295027","https://openalex.org/W2087407849","https://openalex.org/W2092292769","https://openalex.org/W2100511392","https://openalex.org/W2106062658","https://openalex.org/W2106144394","https://openalex.org/W2112858145","https://openalex.org/W2115005218","https://openalex.org/W2118677643","https://openalex.org/W2123914905","https://openalex.org/W2125174117","https://openalex.org/W2130404083","https://openalex.org/W2137752278","https://openalex.org/W2138297714","https://openalex.org/W2140035322","https://openalex.org/W2143782771","https://openalex.org/W2146711059","https://openalex.org/W2149246783","https://openalex.org/W2149456801","https://openalex.org/W2153867442","https://openalex.org/W2156408558","https://openalex.org/W2160476851","https://openalex.org/W2161797239","https://openalex.org/W2162424705","https://openalex.org/W2167093073","https://openalex.org/W2223105525","https://openalex.org/W2225644272","https://openalex.org/W2227074444","https://openalex.org/W2240204773","https://openalex.org/W2240779565","https://openalex.org/W2242487076","https://openalex.org/W2273740586","https://openalex.org/W2284111640","https://openalex.org/W2284587167","https://openalex.org/W2323826290","https://openalex.org/W2406022066","https://openalex.org/W2419377901","https://openalex.org/W2535121273","https://openalex.org/W2590187012","https://openalex.org/W2968909113","https://openalex.org/W3080325851","https://openalex.org/W4232325431"],"related_works":["https://openalex.org/W2100511392","https://openalex.org/W2463862674","https://openalex.org/W1971936145","https://openalex.org/W2090732033","https://openalex.org/W2327241693","https://openalex.org/W2757481782","https://openalex.org/W2080322619","https://openalex.org/W2123851486","https://openalex.org/W2086716921","https://openalex.org/W169489141"],"abstract_inverted_index":null,"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}